Yesterday, Kite Pharma Inc (NASDAQ:KITE) announced positive top-line interim results from its ZUMA-1 pivotal trial in patients with aggressive Non-Hodgkin’s lymphoma (NHL). At …
Kite Pharma Inc (NASDAQ:KITE) announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with …
Kite Pharma Inc (NASDAQ:KITE) announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual …
Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, today reported …
Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT™) products for the treatment of cancer, today announced …
Analysts weighed in how the FDA clinical hold Juno Therapeutics Inc (NASDAQ:JUNO) received affects its business as well as companies with similar drugs …
FBR analyst Edward White is weighing in on biotech firms Juno Therapeutics Inc (NASDAQ:JUNO) and Kite Pharma Inc (NASDAQ:KITE), as both stocks tumbled sharply today following FDA …
Kite Pharma Inc (NASDAQ:KITE) announced results from SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), the first, large, systematic, multi-institutional, patient-level meta-analysis of outcomes from 635 patients …
Kite Pharma Inc (NASDAQ:KITE) announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate …
Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, today provided …
